Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 22, 2011, Pages 9202-9207

  Boltz, Valerie F ^a   Zheng, Yu ^b   Lockman, Shahin ^c   Hong, Feiyu ^d   Halvas, Elias K ^d   McIntyre, James ^e   Currier, Judith S ^f   Chibowa, Margret C ^g   Kanyama, Cecelia ^h   Nair, Apsara ⁱ   Owino Ong'or, Willis ^j   Hughes, Michael ^b   Coffin, John M ^k   Mellors, John W ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e ANOVA HEALTH INSTITUTE   (South Africa)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY TEACHING HOSPITAL   (Zambia)

^h UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

ⁱ FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^j MOI UNIVERSITY   (Kenya)

^k TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Mother to child transmission; Nonnucleoside reverse transcriptase inhibitors

Indexed keywords

LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; TENOFOVIR DISOPROXIL;

ALLELE; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; VIRUS MUTANT; VIRUS RESISTANCE;

ALLELES; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; NEVIRAPINE; POLYMERASE CHAIN REACTION; RISK; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79959352976     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1105688108     Document Type: Article

References (21)

1. Guay LA, et al. (1999) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354:795-802. (Pubitemid 29415583)
2. Jackson JB, et al. (2003) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 362:859-868. (Pubitemid 37130095)
3. Moodley D, et al.; South African Intrapartum Nevirapine Trial (SAINT) Investigators (2003) A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to- child transmission of human immunodeficiency virus type 1. J Infect Dis 187:725-735.
4. Eshleman SH, Jackson JB (2002) Nevirapine resistance after single dose prophylaxis. AIDS Rev 4:59-63. (Pubitemid 34808781)
5. Johnson JA, et al. (2005) Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 192:16-23. (Pubitemid 40863852)
6. Flys T, et al. (2005) Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 192: 24-29. (Pubitemid 40863853)
7. Palmer S, et al. (2006) Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA 103:7094-7099.
8. World Health Organization (2010) Towards universal access: Scaling up priority HIV/ AIDS interventions in the health sector. Progress report 2010 (Geneva, Switzerland).
9. Coovadia A, et al. (2009) Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis 48:462-472.
10. Kuhn L, et al. (2009) Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia. J Acquir Immune Defic Syndr 52:132-136.
11. Lockman S, et al. (2007) Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 356:135-147. (Pubitemid 46089674)
12. Lockman S, et al.; OCTANE A5208 Study Team (2010) Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 363:1499-1509.
13. Mirochnick M, et al. (1998) Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 178:368-374. (Pubitemid 28347918)
14. McIntyre JA, et al. (2009) Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: A randomized clinical trial. PLoS Med 6:e1000172.
15. Chi BH, et al. (2007) Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: An open-label randomised trial. Lancet 370:1698-1705. (Pubitemid 350100773)
16. Lallemant M, et al.; PHPT-4 Study Team (2010) Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine. Clin Infect Dis 50:898-908.
17. Stringer JS, et al. (2010) Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: A multi-country, prospective cohort study. PLoS Med 7:e1000233.
18. Halvas EK, et al. (2010) Low frequency nonnucleoside reverse- transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients. J Infect Dis 201:672-680.
19. Palmer S, et al. (2006) Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 20:701-710. (Pubitemid 43884297)
20. Palmer S, et al. (2005) Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 43:406-413. (Pubitemid 40096331)
21. Boltz VF, et al. (2009) Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design. J Virol Methods 164:122-126.